MedTrace Logo

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

NCT00222625 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2006-09-20

No results posted yet for this study

Summary

Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelets agents

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

rFVIIa + (vit K in AO patients)

DRUG

FFP or aPCC+ vit K in AO treated patients

Sponsors & Collaborators

  • University Of Perugia

    lead OTHER

Principal Investigators

  • Alfonso Iorio · University Of Perugia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222625 on ClinicalTrials.gov